Biotechnology

OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF

NANJING, China, Nov. 17, 2021 /PRNewswire/ -- OncoOne , a biotechnology company focused on discovering precision medicines for cancer and other indications andGenScript ProBio , a leading CDMO in biologics and gene cell therapy, today an...

2021-11-17 22:00 1999

Global Cord Blood Corporation to Report Second Quarter and First Half Fiscal 2022 Financial Results

HONG KONG, Nov. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results fo...

2021-11-17 20:00 2775

European Wellness Join Forces with Heidelberg University Germany in Safety and Toxicity Tests for Preclinical Anti-Aging Peptides Studies

HEIDELBERG, Germany, Nov. 17, 2021 /PRNewswire/ -- European Wellness Academy (EWA), a member of European Wellness Biomedical Group (EWBG), recently signed its second research contract involving General In Vitro/In Vivo Safety and Toxicity Tests for Preclinical Studies of Regenerative Peptides wit...

2021-11-17 16:51 3101

BioAgilytix Secures Significant New Investment from Global Investor Cinven to Fuel Continued Long-Term Growth

Investment Will Provide BioAgilytix with Additional Resources to Invest in Core Business and Drive Growth DURHAM, N.C. and BRUSSELS, Belgium and LONDON, Nov. 17, 2021 /PRNewswire/ -- BioAgilytix, a leading global contract research organization (CRO), today announced an agreement to be further ca...

2021-11-17 15:00 3576

OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF

SINGAPORE, Nov. 17, 2021 /PRNewswire/ -- OncoOne , a biotechnology company focused on discovering precision medicines for cancer and other indications andGenScript ProBio , a leading CDMO in biologics and gene cell therapy, today announc...

2021-11-17 09:10 3285

Recbio Receives Pharmaceutical Production License from Jiangsu Medical Products Administration for Production of COVID-19 Vaccine

TAIZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a biopharmaceutical company focusing on the research, development and commercialization of innovative vaccines that can address prevalent diseases with significant burdens, recently announced that the c...

2021-11-17 09:00 3298

Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe

* The therapy aims to re-energize a patient's immune system to fight cancer tumors * Initial commercialization will target leading oncology centers in Germany, France, Italy, and Spain LAKEWOOD, Colo. and SAN DIEGO, Nov. 16, 2021 /PRNewswire/ --Terumo Blood and Cell Technologies

2021-11-17 00:00 2294

Sofwave™ Announces FDA clearance of New Lifting Indications for Eyebrow, Sub-Mental (beneath the chin) and Neck Facial Areas

The new indications include Eyebrow lifts and lifting of Lax tissue of the Submental and Neck Areas 80% of patients participating in a multi-site clinical trial saw improvement in just 12 weeks TUSTIN, Calif., Nov. 16, 2021 /PRNewswire/ -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in...

2021-11-16 23:23 3860

FibroBiologics Secures $100 Million Capital Commitment from GEM as Company Seeks to Go Public

The Company plans to go public via SPAC, reverse merger, or a direct listing HOUSTON, Nov. 16, 2021 /PRNewswire/ -- FibroBiologics, a clinical stage company developing fibroblast-based therapeutic cures for chronic diseases, announced today that it has signed an agreement with GEM Global Y...

2021-11-16 23:20 1951

FibroBiologics Secures $100 Million Capital Commitment from GEM as Company Seeks to Go Public

The Company plans to go public via SPAC, reverse merger, or a direct listing HOUSTON, Nov. 16, 2021 /PRNewswire/ -- FibroBiologics, a clinical stage company developing fibroblast-based therapeutic cures for chronic diseases, announced today that it has signed an agreement with GEM Global Y...

2021-11-16 23:07 1739

Delivering Health with Science: Huison Virgin DHA at the World Congress of Omega-3 Science & Technology

XIAMEN, China, Nov. 16, 2021 /PRNewswire/ -- The World Congress of Omega-3 Science & Technology, hosted by ISOR, was webcast worldwide onNovember 13 and November 14, 2021. It gathered 28 top experts and heads of relevant industry organizations from around the world who are deeply engaged in Omega...

2021-11-16 21:30 2012

Happiness Development Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

NANPING, China, Nov. 16, 2021 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"),(NASDAQ: HAPP) announced today that the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") onNovember 11, 2021, no...

2021-11-16 21:00 2206

Molecular Stethoscope, Inc. Announces Presentation of Primary Sclerosing Cholangitis (PSC) Study at the AASLD Liver Meeting 2021

Study results demonstrate the utility of the Company's Next-Generation cf-mRNA Liquid Biopsy Technology Platform for the characterization of PSC PALO ALTO, Calif., Nov. 16, 2021 /PRNewswire/ -- Molecular Stethoscope, Inc., a Precision Medicine biotechnology company, announces presentation of its ...

2021-11-16 19:00 1603

Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the appointment ofJohn Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the developme...

2021-11-16 00:00 2718

R&D Milestone: HebaBiz Biotech's application for phase III clinical trial in China for Clevudine (L-FMAU), an anti-hepatitis B virus drug candidate under development has been approved

BEIJING, Nov. 15, 2021 /PRNewswire/ -- HebaBiz Biotech is pleased to announce that inNovember 2021, the Center for Drug Evaluation (CDE) of The National Medical Products Administration (NMPA) ofChina has approved the application for phase III clinical study of Clevudine (L-FMAU), a drug candidate...

2021-11-15 22:47 3473

Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373

GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited (SK bioscience), a biotechnology company inSouth Korea, today...

2021-11-15 22:39 4643

CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA

SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that the European Medicines Agency (EMA) has granted Priority M...

2021-11-15 22:10 7929

Validation Study Showcases Success of LSBD's Rapid SARS-CoV-2 Antibody Test

SYDNEY, Nov. 15, 2021 /PRNewswire/ -- The iQ Group Global Ltd (iQG Ltd) (NSX:IQG) on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), has announced the successful completion of a clinical validation study showcasing the efficacy of its rapid SARS-Cov-2 Antibody test. The results of ...

2021-11-15 22:00 2069

RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients

- Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care - Top-line results for Part A of the study, designed to evaluate safety and tolerability of RHB-107 and dose sel...

2021-11-15 20:00 4493

Seegene Opens New Subsidiary in Bogotá, Colombia, to Advance Regional COVID-19 Testing

SEOUL, South Korea, Nov. 15, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading biotechnology firm specializing in molecular diagnostics (MDx), has announced the opening of an eighth global subsidiary, strategically located in Bogotá,Colombia. The new entity, known as 'Seegene Colombia S.A....

2021-11-15 19:00 2356
1 ... 337338339340341342343 ... 354